The ICGN mouse strain is a glomerulosclerosis (GS) model that shows significant proteinuria, podocyte morphological abnormalities and increased extracellular matrix accumulation in the glomeruli, which represent the final common pathology associated with a variety of kidney diseases leading to end-stage renal failure. Previously, we demonstrated that GS in ICGN mice can be attributed to the deletion mutation of the tensin2 (Tns2) gene (Tns2 nep ). Further, the C57BL/6J (B6) mouse is resistant to GS caused by this mutation. 129/Sv is also a popular strain; however, its susceptibility to GS has not been defined. Thus, to determine whether 129/Sv is resistant or susceptible to GS, we produced a congenic strain carrying Tns2 nep on the 129 +Ter /Sv (129T) background. 129T congenic mice (129T-Tns2 
). Further, the C57BL/6J (B6) mouse is resistant to GS caused by this mutation. 129/Sv is also a popular strain; however, its susceptibility to GS has not been defined. Thus, to determine whether 129/Sv is resistant or susceptible to GS, we produced a congenic strain carrying Tns2 nep on the 129 +Ter /Sv (129T) background. 129T congenic mice (129T-Tns2 nep ) did not exhibit albuminuria, renal anemia, increases in BUN, or any severe pathological changes until at least 16 weeks of age. These results indicate that 129T is resistant to GS. Although their usage in biomedical studies is already widespread, 129/Sv mice may afford a late-onset and unique strain applicable to kidney disease research.
Glomerulosclerosis (GS) is characterized by capillary obsolescence and increased extracellular matrix accumulation, which is the final common pathology in a variety of kidney diseases leading to end-stage renal disease. Development of proteinuria is due to injury of the glomerular filtration barrier, which consists of the glomerular endothelium, the glomerular basement membrane (GBM), and podocytes outside the glomerular capillary. Several lines of evidence suggests that podocytes act as the main component of this barrier because mutations in a number of podocyte-specific genes (NPHS1, NPHS2, CD2AP, ACTN4, TRPC6, PLCE1, MYH9) responsible for GS were identified (6, 17) . Therefore, podocyte loss is a common determining factor for progression toward many types of kidney disease (17) . However, the mechanisms responsible for podocyte loss in response to injury are still unknown. Although knockout mice for GS-causative genes have been developed, these mice died of severe kidney failure by about 1-2 months after birth, limiting the usefulness of these models in exploring the pathogenesis of GS and the development of new treatments for GS (5, 12, 14, 16) . ICGN mouse is an inbred strain that exhibits the pathological hallmarks of GS, diffuse/global glomerular lesions characterized by marked glomerular hypertrophy, mesangial expansion, foot process effacement of podocytes and thickening of the GBM (9, 10) . Previously, we performed a quantitative trait locus (QTL) analysis to isolate the causative genes for these phenotypes, and identified a major QTL on 110072). Urine samples were collected from the bladder and urinary albumin was measured using Albuwell M (Exocell Inc.). Blood tests were performed as described previously (7) . Sections (2-μm thick) were prepared from paraffin-embedded kidney tissues and stained with periodic acid-Schiff (PAS) reaction. All statistical comparisons were performed by using the two-tailed multiple t-test with Bonferroni correction between sex-matched groups (two comparisons in three groups). All values were presented as means ± SD, and differences were considered significant at P < 0.05. Albuminuria is a functional indicator of disease Chr 15, which is identical to a single recessive locus causing GS, previously designated as the nep locus in the ICGN mouse. Further, we identified a deletion mutation in the tensin2 (Tns2) gene and concluded that the Tns2 is the causative gene of GS (2) . ICGN mice show proteinuria at a young age, and anemia and edema develop with aging similar to human chronic kidney disease (CKD). Thus, ICGN mice are thought to be a good model for human CKD since most of other model animals show acute and severe progression of nephrotic syndrome within a short time span. Susceptibility to GS has been believed to be associated with a genetic background in humans and other animals. This genetic effect is often complex and difficult to identify since it is further modified by environmental factors. Laboratory mice afford a useful alternative for identifying factors that contribute to disease progression as variations among strains, and allow the identification of genes associated with resistance or susceptibility to GS. Thus, we previously developed the C57BL/6J (B6) congenic mice (B6-Tns2 nep ) that carry the Tns2 nep mutation. Interestingly, the B6-Tns2 nep mice exhibited milder phenotypes than did ICGN strain mice. The results suggest that B6 mice possess modifier(s) of GS resistance (8) . 129Sv mouse strains are widely used in gene-targeting experiments. The embryonic stem cells derived from 129Sv mice are part of the genetic background of most mutants generated using homologous recombination. However, the susceptibility to renal disease in 129Sv mice has not been demonstrated to date. Thus, we produced congenic strains for Tns2 nep in 129 +Ter /Sv (129T) (Clea Japan) mice. The congenic strain was produced by backcrossing ICGN to 129T mice for more than 10 generations (designated 129T-Tns2 nep ). Genotyping of the nep allele was performed as described previously (8) . The heterozygotic congenic females and males were crossed with each other, and nep homozygote, heterozygote and WT mice were born according to the Mendelian rule. The 16-18 week-old animals were selected for the analysis because the ICGN mice show hyalinization in all glomeruli, heavy albuminuria and anemia, which are the end stages of a variety of pathologic conditions. A humane end point was applied when the severely anemic ICGN mice became moribund. All research and experimental protocols were adhered to the Regulation for the Care and Use of Laboratory Animals, Hokkaido University and approved by the President of Hokkaido University following to the review of the Institutional Animal Care and Use Committee. (approval ID: No. males was normal, and a slight decrease in hemoglobin level was observed in 129T-Tns2 nep females (Fig. 1C) . The reason for this gender difference remains unclear, although it might be related to the differential effects of male and female sex hormones. To confirm whether the results of albuminuria analysis and blood test are related to the histopathology of the kidney, histological analysis was also carried out. Fig. 2 shows representative PAS-stained sections demonstrating the pathological changes in the kidney in each strain female. The kidney of the ICGN mice showed pathological changes typical of GS; e.g., podocytopenia, mesangial expansion, glomerular hyalinization, urinary cast and glomerular and tubular basement membrane thickening at 16 weeks of age (Fig. 2D) . By contrast, the kidneys of 129T-Tns2 nep mice appeared normal as 129T-WT mice ( Fig. 2A, C) , though a part of Bowman's capsule basement membrane became progression through renal parenchymal damage; therefore, we measured the amount of albumin in the urea at 16 weeks of age. In the ICGN mice, severe albuminuria was observed at 16 weeks of age. Interestingly, no albuminuria was observed in the 129T-Tns2 nep mice (Fig. 1A) . Even 37-week-old congenic males did not exhibit albuminuria (data not shown). Next, to assess the progression of GS, we measured the plasma blood urea nitrogen (BUN) and hemoglobin levels in ICGN and 129T-Tns2 nep mice. In 129T-Tns2 nep male mice, the plasma level of BUN was significantly lower than that in ICGN male mice, and the same trend was also observed in female though not reaching statistical significance (Fig. 1B) . There were no significant differences between 129T-WT and congenic mice of either sex. In addition, a significant decrease in hemoglobin level was observed in ICGN mice exhibiting severe anemia. In contrast, the hemoglobin level in 129T-Tns2 slightly thick and the spike-like pattern appeared in GBM (Fig. 2B) . There was no obvious sex difference in kidney pathology (data not shown). Together with the data for proteinuria, BUN and hemoglobin level, these results indicate that the 129T strain has considerable resistance to GS and there are no obvious abnormalities apart from a slight decrease in hemoglobin in females. Even in 129T-Tns2 nep males at 37 weeks of age, most glomeruli appeared normal and there was only a moderate increase in the amount of extracellular matrix and vascular lesions (data not shown). Most gene targeting is carried out with cultured ES cells derived from the 129 strain because of its higher efficiency of germline transmission. However, the genetic and phenotypical differences from several common strains remain an impediment to researchers. For example, corpus callosum dysgenesis, which confounds studies of behavioral and cognitive phenotypes, is commonly observed in 129 mouse strains (4) . Further, the immune response of 129 strains differs from the well-characterized responses of B6 mice (1, 12, 15) . Our data suggests that the 129T strain is a unique strain that may be particularly suited to CKD research. In this study, our results provide the first demonstration that the 129T strain has a genetically high resistance to GS. Most forms of GS appear sporadically, and the incomplete penetrance and the variable expression observed in familial cases of GS demonstrate that GS is a genetically heterogeneous disease (3, 11) . For this reason, there is little information available on the genetic factors associated with GS. Here, we could not find out the clinical and pathological differences between B6-Tns2 nep and 129T-Tns2 nep at least until 16-18 weeks of age. We will need a long-term observation for a year to judge these strain differences. Further studies are required to understand the exact mechanism of the resistance/susceptibility to renal disease in our strains. Nevertheless, the present study provides a first step in the identification of novel modifier gene(s) that might lead to the development of treatment strategies for GS and CKD.
